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Abstract: 
It has been postulated that immunogenicity results from the overall dissimilarity of pathogenic proteins versus the host proteome. We have 
sought to use this concept to discriminate between antigens and non-antigens of bacterial origin. Sets of 100 known antigenic and non-
antigenic peptide sequences from bacteria were compared to human and mouse proteomes. Both antigenic and non-antigenic sequences 
lacked human or mouse homologues. Observed distributions were compared using the non-parametric Mann-Whitney test. The statistical 
null hypothesis was accepted, indicating that antigen and non-antigens did not differ significantly. Likewise, we were unable to determine a 
threshold able to separate meaningfully antigen from non-antigen. Thus, antigens cannot be predicted from bacterial genomes based solely 
on their dissimilarity to the human genome. 
 
Background: 
It is a verity now universally acknowledged that population-level 
vaccination is the most effective preventative measure discovered 
thus far for the control of infectious disease and for subsequently 
mitigating the effects of re-infection. A vaccine is a molecular or 
supramolecular agent able to engender specific protective immunity, 
an enhanced adaptive immune response to re-infection by 
pathogens. Immunity  is characteristic of proper immune system 
functioning and manifests itself in the ability of the host to tolerate 
endogenous, somatic substances and to eliminate exogenous, 
foreign material. This discrimination defends us against diverse 
infectious diseases, since microbial products are readily seen by the 
immune system as alien products. Protection results in the 
potentiation of host survival and the destruction of pathogens [1].  
 
Vaccines themselves come in various guises. Some may be living 
but weakened - or attenuated - strains of micro-organisms that have 
been cultured under conditions which reduce their capacity to cause 
disease and thus give rise only to mild or undetectable infections; 
and include those acting against measles, rubella, yellow fever, 
mumps, and tuberculosis. Such vaccines reduce the intrinsic 
virulence exhibited by a virulent microorganism, typically by 
altering their growth conditions, yet leave their immunogenic 
properties largely unaffected. Vaccines may also be killed or 
inactivated organisms treated with heat or chemicals; examples 
include vaccines active against Influenza, cholera, bubonic plague, 
polio, hepatitis A, and Rabies. So-called subunit vaccines are a third 
form of vaccine. They comprise individual pathogenic proteins, and 
examples include vaccines against HBV, Human Papillomavirus, 
and  Haemophilus influenzae B. Subunit vaccines, consisting of 
highly immunogenic carbohydrate, such as cell wall components; 
protein; or glyco-protein conjugates, stimulate measurable yet often 
quite weak immune responses, necessitating the use of adjuvants to 
raise initial levels of immunogenicity and also complex vaccination 
regimes to sustain enduring protection. Yet despite such drawbacks, 
subunit vaccines remain a popular objective and are thus a current 
focus for vaccine discovery.  
 
In the era of reverse vaccinology, we may pose ourselves the 
question: given the genome of a pathogen, how do we choose 
appropriate antigens as efficacious candidate subunit vaccines? The 
immunogenicity of an antigen arises no doubt from a complex 
interplay of factors. Traditionally, people have seen sub-cellular 
location as a prime determinant: immunogenic proteins need to be 
accessible to surveillance by the immune system; and as such they 
are likely to be secreted or located on the cell surface. Others have 
sought to use sequence similarity to identify antigens [2] or 
developed non-parametric methods to predict antigen status [3, 4]. 
Yet another alternative postulates that the immunogenicity of a 
protein is determined by its overall lack of similarity to the host 
proteome [5]. This idea is, in its simplicity and directness, quite 
compelling. Based upon this assumption, and through the use of the 
sequence similarity search tool BLAST, we attempt here to leverage 
sequence similarity to discriminate effectively antigen from non-
antigen and establish a threshold that ostensibly separates the two 
classes. If successful, such an undertaking would constitute a 
significant advance in rational vaccine design. More specifically, we 
sought to analyse the degree of similarity between known bacterial 
antigens and the Human Genome and Mouse Genome, compared 
with a control group of non-antigens, and thus establish a systematic 
benchmark for such a strategy.  
 
Methodology: 
Sequence similarity comparison of antigen datasets, non-antigen 
datasets and various pathogenic genome sequences to the Human 
and Mouse Genome was performed using a local, standalone 
version of BLAST [6], which allowed full control of E-value cut-off 
and of the substitution matrix used. E-value thresholds were raised 
from 10 to 6000 to identify best matches even when these lacked 
statistical significance.  Seven substitution matrices were examined: 
BLOSUM45, BLSOUM62, BLOSUM80, BLOSUM90, PAM30, 
PAM70 and PAM250. Datasets of 100 known antigens obtained 
from the literature and 100 non-antigens from bacteria were 
analysed [3]. Non-antigens were selected from SWISSPROT so that 
they mirrored the antigen sets, being selected stochastically from the 
same set of species [3, 4]. Bacterial antigens used are listed in 
Figure 1. Additionally, genomes corresponding to Human, Mouse, 
and Bacteria were downloaded from FTP sites at National Center 
for Biotechnology Information (NCBI) [http://www.ncbi.nlm. nih. 
gov/], European Bioinformatics Institute (EBI) [http://www.ebi.ac. 
uk/], and Ensembl [http://www.ensembl.org/]. Looking at (log10
E-
value) +1 values from BLAST, the Mann–Whitney – or two-sample 
rank - test was used to compare the bacterial antigen and non-
antigen sets, as random samples of two larger, independent 
populations, using the statistical package Minitab, Release 14.1. 
 
Discussion: 
A dataset comprising 100 known bacterial literature protein 
antigens, as well as a control set of 100 bacterial protein non-
antigens [3, 4], were compared against the Human and Mouse 
Genomes, resulting in lists of the highest scoring similarities. For 
completeness, a similar analysis for five whole bacterial genomes 
(Escherichia coli, Chlamydophila pneumoniae, Haemophilus 
influeanzae, Salmonella typhi and Mycobacterium tuberculosis) was 
also undertaken.  All sets analysed were similarly distant to both 
mouse and human genomes. Scores for antigen, non-antigen, and E. 
coli proteome versus the human proteome are plotted in Figure 2. It 
is clear that the three overall distributions strongly overlap, and that 
no cut-off point is apparent. 
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Figure 1: Protein sequences compiled and annotated in-house as Bacterial antigens. 
 
 
Figure 2: A sequence similarity comparison with the E-value as 6000 and BLOSUM 62 matrix, between the Antigen, Non-antigen and E-
coli genome sequences. Two separate scales were used as the number of matches to the Human Genome varied from the antigen and non-
antigen datasets to the genome. The blue line with the star marker symbolizes the genome is plotted on the scale to the right hand axis (Y 
axis). 
 
We also analysed the effect of modifying BLAST parameters (data 
not shown), primarily by varying the substitution matrix. Such 
matrices purportedly measure the probability of evolutionary 
divergence of the protein to develop an evolutionary protein model. 
Technical practicalities limited us to 7 matrices: 4 BLOSUM series 
and 3 PAM series matrices. To a first approximation, the use of 
different matrices makes no operationally significant difference: 
although individual values varied, the shape and structure of the 
plotted score distributions remained largely unaltered. Moreover, 
the ability to discriminate antigens from non-antigens was 
essentially unaffected.  
 
We also assessed the statistical significance of differences between 
distributions of scores using the Mann-Whitney test, a non-
parametric statistical method, which tests the differences in medians 
rather than means, since the population being analysed was skewed 
and un-normalised. We used two different confidence intervals: 
90% and 95%; p-values were the same for each. Although p-values Bioinformation   open access 
www.bioinformation.net    Hypothesis
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for several of the PAM and BLOSUM matrices were marginally 
significant, overall - and in accordance with our visual 
interpretations - the test established the statistical null hypothesis 
that the apparent differences resulted solely from chance. The most 
promising results came with the use of the PAM30 matrix, but even 
here the result was again marginal and poorly predictive. 
 
Overall, and given our original objectives, these results can be seen 
as disappointing, yet they leave no doubt that there is no obvious 
and significant difference between bacterial antigens and bacterial 
proteins or proteomes deemed to be non-antigens, and there is 
certainly no clear and unequivocal means to differentiate the two 
sets simply on the basis of scores. The non-antigen set seems to 
contain marginally more proteins that are more similar to the 
eukaryotic host proteomes than the antigen set, though this may be a 
statistical quirk due to the limited data set we use. It may thus be 
that when dissimilarity screening versus the human proteome is 
used in concert with other properties characteristic of antigens, such 
a technique predicated on dissimilarity will in part prove useful, at 
least in terms of rejecting a portion of the bacterial genome as low-
likelihood candidates. However, as a tool for vaccine discovery, 
dissimilarity is in itself of limited utility, at least for Bacteria and as 
the sole arbiter of immunogenicity. 
 
Thus, a key feature of future work would be to integrate this 
approach with other nascent techniques for antigen identification. 
Other work might include making use of more sophisticated 
approaches available for sequence similarity analysis, such as 
PatternHunter [7]. Rather than use pairwise alignment, use could be 
made of multiple sequence alignment to derive distances, as 
implemented in say T-coffee [8]. Likewise, the more sophisticated 
scoring available in phylogenetic software, such as PHYLIP or 
PALM [9], could prove useful. In terms of analysing data, some 
virtue may be gained by using Operating Characteristic (ROC) plots 
and the 2 sample Kolmogorov Smirnov test to compare 
distributions.  
 
Conclusion: 
The hypothesis of Kundac et al. [5] is undeniably compelling. 
However, our examination provides evidence that contradicts this 
hypothesis, at least as we restate it: that non-redundancy is key to 
predicting candidate vaccine antigens. To abbreviate our story: we 
were unable to determine a suitable threshold able to differentiate 
antigens from non-antigens on the basis of similarity to the host’s 
proteome. Both antigens and non-antigens were, to a first 
approximation, essentially equally dissimilar to host proteomes, and 
about as dissimilar as the background distribution provided by 
whole bacterial genomes. We conclude that straightforward 
dissimilarity searching is not a suitable approach for selecting 
candidate vaccine antigens from bacteria. We are currently pursuing 
more sophisticated and successful approaches, so far without 
success.  
 
Protein immunogenicity arises from many factors. These include 
host-side properties - possession of B or T cell epitopes for example 
- and pathogen-side properties - protein expression levels and sub-
cellular location - as well as its aggregation state and the possession 
of post-translational danger signals. A candidate vaccine should be 
highly expressed, available for immune surveillance, and possess 
epitopes that the host recognises. Predicting such diverse properties 
remains challenging, though several contributing factors can be 
reliably predicted. What we need is an integrative, systems biology 
approach to the problem. Our search for such an approach 
continues.  
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